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Interstitial cystitis (IC) is a severely debilitating, still puzzling, 
heterogeneous syndrome affecting the urinary bladder that is 
associated with pelvic pain and voiding symptoms of urgency, 
frequency, and nocturia [1]. Despite many continuing efforts to 
ascertain the etiology and pathophysiology of IC, our knowl-
edge remains fragmentary and has failed to provide useful in-
sights into effective treatments. Various treatment modalities 
are currently available to treat patients with IC, but none is par-
ticularly effective. New effective treatments will not be available 
until the etiology of the disease is better understood and the core 
factors involved in its pathophysiology are better identified. Thus, 
this is a good time to refresh and upgrade our information re-
lated to IC from the view of fields outside of urology. 
  The idea that IC is an inflammatory response induced by tox-
ic, allergic, or immunologic pathogens in the urine is still the 
most convincing theory on the pathogenesis of the disease. Fur-
thermore, most studies in humans and animals have focused on 
the central role of mast cells in IC, although ongoing controver-
sy exists over the detailed mechanisms [2]. Allergic inflamma-
tory responses in urologic organs share many characteristic bio-
chemical and cellular features with organs beyond urology, in 
which the mast cell is also considered to be one of the key effec-
tor cells of the allergic reaction. Recently, a new therapeutic ap-
proach based on new biological insights has emerged to better 
control mast cell function. For example, activation of inhibitory 
receptors on mast cells by use of antibodies or small molecules 
for their selective targeting has been shown to be clinically ef-
fective. Furthermore, at least in immune systems, regulation of 
these bindings may result in subsequent down-regulation of cell 
function. 
  The vertebrate immune system maintains normal immune 
cell homeostasis by modulating immune responses through the 
interplay of activation and inhibition. The cell system of inhibi-
tory signaling is especially crucial for this balancing. Loss of in-
hibitory signaling may result in autoimmune disease. Since the 
sialic-acid-binding immunoglobulin-like lectins (Siglecs) were 
identified for the first time as markers of leukemia and lympho-
ma 30 years ago [3], they have become known as important in-
hibitory regulators of immune cell signaling. Their structural 
features include an N-terminal carbohydrate-binding (lectin) 
domain that binds sialic acid and immunoreceptor tyrosine-
based inhibitory motifs (ITIMs) in their cytoplasmic domains. 
The ITIMs are responsible for their inhibitory capacity [4]. Si-
glec-8, the eighth member identified, was discovered as part of 
an effort to find new eosinophil surface proteins. Subsequent 
studies showed that mast cells also selectively express Siglec-8 
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and showed an inhibition of degranulation without apoptosis 
by crosslinking of Siglec-8, whereas on eosinophils, Siglec-8 en-
gagement resulted in apoptosis [3]. 
  Thus, the selective targeting of particular Siglecs such as Si-
glec-8 on the mast cell could one day be useful in the armamen-
tarium for the treatment of IC. Such targeting could result in the 
down-regulation of mast cells where overproduction of mast cells 
is occurring. 
  The article by Park and Bochner [5] in this issue of the jour-
nal will be recognized as a valuable work in the IC field that ini-
tiates future research into the inhibitory control of mast cells via 
manipulation of Siglecs. 
REFERENCES
1. Oberpenning F, van Ophoven A, Hertle L. Interstitial cystitis: an 
update. Curr Opin Urol 2002;12:321-32.
2.   Theoharides TC, Kempuraj D, Sant GR. Mast cell involvement in 
interstitial cystitis: a review of human and experimental evidence. 
Urology 2001;57(6 Suppl 1):47-55.
3. Bochner BS. Siglec-8 on human eosinophils and mast cells, and Si-
glec-F on murine eosinophils, are functionally related inhibitory 
receptors. Clin Exp Allergy 2009;39:317-24.
4. O’Reilly MK, Paulson JC. Siglecs as targets for therapy in immune-
cell-mediated disease. Trends Pharmacol Sci 2009;30:240-8.
5. Park CS, Bochner BS. Potential targeting of siglecs, mast cell inhibi-
tory receptors, in interstitial cystitis. Int Neurourol J 2011;15:61-3.